ArticlePatient preference and adherence2026
Real-World Canadian Insights into Pediatric Growth Hormone Deficiency: Perspectives on Daily and Long-Acting Growth Hormone from Patients, Caregivers, and Healthcare Providers.
Article in Patient preference and adherence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Many patients with growth hormone deficiency (GHD) do not reach their target height in adulthood which is largely linked to treatment non-adherence. Patients report preferring a less frequent treatment regimen. Research is needed to explore reasons for non-adherence and treatment regimen preferences in patients with GHD. The purpose of this study was to explore GHD treatment preferences in health care practitioners (HCPs), patients with GHD aged 12-17 years, and caregivers of patients with GHD aged 3-17 years living in Canada. Patients and Methods: This qualitative interview study comprised of 60-minute interviews with Canadian HCPs, adolescents with GHD, and caregivers of pediatric patients. Interviews explored treatment decisions, adherence, access barriers, and preferences between daily and once-weekly growth hormone treatment regimens. Thematic analysis of interview transcripts was conducted. Results: 12 HCPs and 25 patient/caregiver interviews were completed. Limited awareness of once-weekly treatments and equity issues were observed across all participant groups. Most caregivers and patients preferred once-weekly injections for convenience and reduced burden. Emotional and logistical challenges were noted, especially for daily regimens. HCPs reported positive transitions to once-weekly regimens, though concerns remain about long-term data and coverage. Preferences leaned toward less invasive formats (e.g, pills) and medications that do not require refrigeration. Conclusion: This study explored experiences of Canadian GHD patients, caregivers, and HCPs, revealing strong preferences for once-weekly GH treatment due to convenience and reduced burden. Findings also highlighted gaps in treatment awareness, support, and education, emphasizing the need for targeted information and expanded patient resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.